#stayhome Maintain the distance, wash your hands, and follow instructions from the health authorities.
RSS   Newsletter   Contact   Advertise with us

Dicerna Pharma names Ralf Rosskamp as CMO

Share on Twitter Share on LinkedIn
Staff Writer | Cambridge, Mass., USA | June 9, 2017
Dicerna PharmaceuticalsJune 9, 2017, Cambridge, Mass., USA - Dicerna Pharmaceuticals, a developer of investigational ribonucleic acid interference (RNAi) therapeutics, appoints industry veteran Ralf Rosskamp as chief medical officer, effective June 15, 2017.
Dr. Rosskamp brings to Dicerna more than 20 years of research and development (R&D) experience spanning the entire drug development cycle, from pre-clinical through product commercialization.

Dr. Rosskamp joins Dicerna from Summit Therapeutics where he served as chief medical officer.

Prior to Summit, Dr. Rosskamp held executive-level positions in clinical research and drug development at NPS Pharmaceuticals (acquired by Shire), Ikaria, Kos Pharmaceuticals (acquired by Abbott Laboratories), Aventis Pharmaceuticals (formerly Hoechst Marrion Roussel), and Hoechst AG.

 LATEST MOVES FROM Massachusetts